Clinical Study

Atypical Antipsychotics in the Treatment of Depressive and Psychotic Symptoms in Patients with Chronic Schizophrenia: A Naturalistic Study

Table 1

Differences between groups.

Clozapine
( )
Other antipsychotics
( )
Test <

Characteristics at the baseline
 Age (M ± SD)38.48 ± 11.4545.39 ± 12.16 0.07
 Men (%)65.269.60.50
 Diagnosis (%)0.05
 Schizophrenia87.056.5
 Psychotic Disorder NOS13.043.5
 Age at onset (M ± SD)22.91 ± 6.8826.22 ± 7.20 0.05
 Years since diagnosis (M ± SD)15.17 ± 8.1118.57 ± 10.74 0.26
 Risperidone (%)19.6
 Olanzapine (%)19.6
 Quetiapine (%)6.5
 Aripiprazole (%)2.2
 Psychotic episodes ≥ 5 (%)43.530.40.27
 Schizophrenia in the family members (%)13.026.10.23
 PANSS positive symptoms at the baseline (M ± SD)22.87 ± 6.8217.83 ± 6.83 0.05
 PANSS negative symptoms at the baseline (M ± SD)30.65 ± 9.2424.70 ± 9.72 0.07
 PANSS general symptoms at the baseline (M ± SD)48.61 ± 13.1044.96 ± 12.02 0.34
 CDSS at the baseline (M ± SD)2.78 ± 4.024.50 ± 3.85 0.05
 CDSS ≥ 5 (%)30.440.90.34
 SUMD awareness (M ± SD)21.91 ± 11.2416.95 ± 10.27 0.10
 SUMD symptoms attribution (M ± SD)23.74 ± 11.1417.05 ± 11.32 0.054
Characteristics at the follow-up
 Clozapine doses (mg (range)) (M ± SD)410.87 ± 127.88 (200/750)
 Years of treatment with the current antipsychotic (M ± SD)5.36 ± 5.314.70 ± 2.22 0.66
 Suicidal ideation (%)26.121.70.50
 Suicide attempts (%)13.017.40.50
 Change from baseline in the PANSS positive symptoms (M ± SD)−8.43 ± 8.88−6.70 ± 7.56 0.24
 Change from baseline in the PANSS negative symptoms (M ± SD)−4.78 ± 11.07−6.87 ± 10.57 231.00 0.46
 Change from baseline in the PANSS general symptoms (M ± SD)−8.96 ± 17.23−13.39 ± 17.32 0.47
 Change from baseline in the CDSS (M ± SD)0.48 ± 5.29−2.05 ± 4.50 0.05
 CDSS response* (%)71.460.00.52
 Change in the SUMD awareness (M ± SD)−6.71 ± 6.85−7.92 ± 4.96 0.29
 Change from baseline in the SUMD symptoms attribution (M ± SD)−7.81 ± 7.41−6.62 ± 3.93 0.97

had been defined as a 50% change of baseline scores for patients with a CDSS score of 5 and higher at the baseline.